GLP-1 for Men: Weight Loss, Dosing, and What to Expect

Is any GLP-1 drug approved for men specifically?

No. The weight-management labels define who qualifies by body mass index and weight-related conditions, not by sex. Wegovy is indicated for adults with obesity, or with overweight plus at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity [1]. The Foundayo label uses the same obesity-or-overweight-with-a-comorbidity wording [4], and SURMOUNT-1 enrolled adults on those same BMI thresholds [6].

Men are in the trial populations, but often a minority. The Wegovy weight-management trials that supported the 2.4 mg injection enrolled 2,116 treated adults and were 71% female [1]. In the two Foundayo weight-management trials, 41% of participants were male [4]. The average results below therefore come from men and women combined; there is no separate male label or male dose.

How much weight loss do the trials show?

The figures below are mean percent change in body weight.

Semaglutide 2.4 mg (STEP 1): 1,961 adults with obesity or overweight and no diabetes, 68 weeks, alongside lifestyle intervention. Weight change was 14.9% loss with semaglutide versus 2.4% with placebo. At least 5% weight loss occurred in 86.4% versus 31.5%, at least 10% in 69.1% versus 12.0%, and at least 15% in 50.5% versus 4.9% [5].

Tirzepatide (SURMOUNT-1): 2,539 adults with obesity or overweight and no diabetes, 72 weeks. Weight change was 15.0% loss at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% with placebo [6].

Tirzepatide versus semaglutide (SURMOUNT-5): 751 adults with obesity and no diabetes, open-label, 72 weeks, each drug at its maximum tolerated dose. Weight change was 20.2% loss with tirzepatide and 13.7% with semaglutide; waist circumference fell 18.4 cm versus 13.0 cm [7]. This is the direct comparison, and it favors tirzepatide.

Liraglutide (Saxenda label study): 3,731 adults with obesity or overweight plus a comorbidity, 56 weeks. Weight change was 7.4% loss versus 3.0% with placebo, and at least 5% weight loss occurred in 62.3% versus 34.4% [2].

Orforglipron (Foundayo label trials): Trial 1 enrolled 3,127 adults with obesity or overweight and no diabetes for 72 weeks; weight change was 7.4% loss at 5.5 mg, 8.3% at 9 mg and 11.1% at 17.2 mg, versus 2.1% with placebo [4].

With type 2 diabetes, weight loss is smaller. In STEP 2, 1,210 adults with type 2 diabetes lost 9.6% of body weight on semaglutide 2.4 mg versus 3.4% on placebo at 68 weeks [9]. In SURMOUNT-2, 938 adults with type 2 diabetes lost 12.8% at 10 mg and 14.7% at 15 mg versus 3.2% on placebo at 72 weeks [10]. In Foundayo Trial 2, 1,613 adults with type 2 diabetes lost 5.1%, 7.0% and 9.6% versus 2.5% [4].

Dosing: what the labels say

The Wegovy and Foundayo labels direct a low starting dose and stepwise escalation to reduce the risk of gastrointestinal adverse reactions [1][4].

Wegovy injection (weekly): 0.25 mg for weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg at four-week intervals, reaching maintenance at week 17. The maintenance dose for weight reduction is 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended [1]. The label also allows an increase to a maximum of 7.2 mg weekly for adults who tolerate 2.4 mg for at least 4 weeks and in whom additional weight reduction is clinically indicated [1]. The label says to inject under the skin of the abdomen, thigh or upper arm, on the same day each week, at any time of day, with or without meals [1].

Wegovy tablets (daily): start at 1.5 mg once daily for 30 days, then escalate every 30 days to a maintenance dose of 25 mg once daily for weight reduction and cardiovascular risk reduction [1]. The label says to take the tablet on an empty stomach in the morning with up to 4 ounces of water and to wait at least 30 minutes before food, other drinks or other oral medicines [1].

Foundayo (daily tablet): start at 0.8 mg once daily, move to 2.5 mg after at least 30 days, then to 5.5 mg after at least another 30 days, and then step up to 9 mg, 14.5 mg or 17.2 mg at intervals of at least 30 days as tolerated. The maximum is 17.2 mg once daily, and it can be taken with or without food [4].

Saxenda (daily injection): liraglutide is given once daily, unlike the weekly semaglutide and tirzepatide injections [2].

Zepbound (weekly injection): tirzepatide is given once weekly [3]; the doses tested for weight management in SURMOUNT-1 were 5, 10 and 15 mg [6].

The Wegovy, Saxenda, Zepbound and Foundayo labels all say concomitant use with another GLP-1 receptor agonist is not recommended [1][2][3][4].

Side effects and risks worth knowing

Gastrointestinal effects are the class signature, and they cluster during dose escalation. With Wegovy 2.4 mg, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11% [1]. With Foundayo 17.2 mg, nausea occurred in 35% versus 10%, vomiting in 24% versus 4%, diarrhea in 25% versus 11% and constipation in 24% versus 9% [4]. Permanent discontinuation because of adverse reactions was 6.8% versus 3.2% for Wegovy 2.4 mg [1] and 8% versus 3% for Foundayo overall, rising to 10% at 17.2 mg [4].

Hair loss is listed as a common reaction on both labels, and the Foundayo data show a sex difference: 5% versus 2% overall at 17.2 mg, but 7% of women versus 0.9% of men [4]. Wegovy reports hair loss in 3% versus 1% [1].

The prescribing information warns that heart rate can increase during treatment with Wegovy, Foundayo and tirzepatide [1][4][3].

Serious risks named in the labels include acute pancreatitis, acute gallbladder disease, acute kidney injury from dehydration, and hypoglycemia when combined with insulin or a sulfonylurea, where the label advises considering a lower dose of the insulin or sulfonylurea at the start [1][4]. The Wegovy, Foundayo and tirzepatide labels say the drug delays gastric emptying [1][4][3]. The Wegovy label reports pulmonary aspiration in patients receiving GLP-1 receptor agonists who underwent elective surgeries or procedures under general anesthesia or deep sedation, and says to instruct patients to inform healthcare providers of any planned surgery or procedure [1].

The boxed warning covers thyroid C-cell tumors seen in rodents, with human relevance undetermined, and the drugs are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 [1][4]. Foundayo has the same contraindication but different boxed-warning wording: orforglipron was not pharmacologically active in rats or mice and did not produce tumors in rodents, while the human relevance of GLP-1-receptor-dependent rodent tumors has not been determined [4]. Separately, FDA concluded in January 2026 that GLP-1 receptor agonists show no increased risk of suicidal behavior or ideation and asked makers to remove that warning; the Saxenda, Wegovy and Zepbound labels have since removed it [11][2][1][3].

What happens when you stop

In STEP 4, weight came back after semaglutide was stopped. In that trial, 803 adults who had completed a 20-week semaglutide run-in were randomly assigned to keep taking semaglutide 2.4 mg or switch to placebo for 48 more weeks. Those who continued lost another 7.9% of body weight; those switched to placebo regained 6.9% [8].

Heart risk and cardiovascular benefit

Wegovy is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [1]. The supporting trial, SELECT, enrolled 17,604 adults with established cardiovascular disease and a BMI of 27 or higher but no diabetes. The composite of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% on semaglutide versus 8.0% on placebo over a mean follow-up of 39.8 months, a hazard ratio of 0.80 [12].

Testosterone and weight loss in men with type 2 diabetes

A 2011 review of low testosterone in men with type 2 diabetes notes that low testosterone is common in these men and that lifestyle measures such as weight loss and exercise, if successful, raise testosterone [13]. That review addresses weight loss in general, not GLP-1 drugs.

Diabetes products versus weight-management products

The weight-management products are Wegovy, Saxenda and generic liraglutide for weight, Zepbound and Foundayo. Ozempic, Rybelsus, Victoza, Trulicity, Byetta, Mounjaro, Soliqua and Xultophy are approved for type 2 diabetes, not for weight management [1][2][3][4]. Tirzepatide is also not a pure GLP-1 drug: its label describes it as a GIP and GLP-1 receptor agonist, a dual agonist [3].

Compounded semaglutide and compounded tirzepatide are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [14]. FDA has also warned about dosing errors involving compounded GLP-1 drugs [14].